Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.44 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12403885 | 1.00 | LRRK2 (0.46) | LRRK2CCR5PTGER1CYP1A2USP2 | |
| SCHEMBL15148415 | 1.00 | LRRK2 (0.46) | LRRK2CCR5PTGER1CYP1A2USP2 | |
| SCHEMBL1783943 | 0.90 | KMT2A (0.47) | LRRK2CCR5PTGER1USP2LMNA | |
| SCHEMBL2167632 | 0.90 | KMT2A (0.47) | LRRK2CCR5PTGER1USP2LMNA | |
| SCHEMBL2166135 | 0.90 | KMT2A (0.47) | LRRK2CCR5PTGER1USP2LMNA | |
| SCHEMBL12293726 | 0.88 | CCR5 (0.47) | LRRK2CCR5PTGER1CYP1A2USP2 | |
| SCHEMBL1355279 | 0.86 | HTT (0.50) | LRRK2CCR5USP2LMNAUSP28 | |
| SCHEMBL1992692 | 0.85 | FOLH1 (0.42) | PTGER1LMNARAB9AHPGDHTT | |
| SCHEMBL1992690 | 0.85 | FOLH1 (0.42) | PTGER1LMNARAB9AHPGDHTT | |
| SCHEMBL1989522 | 0.85 | PTGER1 (0.46) | LRRK2PTGER1ALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338478-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-7985772-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2011-07-26 | — | — | US | disclosed |
| US-7855230-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2010-12-21 | — | — | US | disclosed |
| US-20100256231-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | UCB PHARMA GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20090042981-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-7384980-B2 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2008-06-10 | — | — | US | disclosed |
| US-7230030-B2 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060270738-A1 | Novel derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2006-11-30 | — | — | US | disclosed |
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG | 2004-09-23 | — | — | US | disclosed |
| US-6713464-B1 | ANTIMUSCARINIC AGENTS WITH SUPERIOR PHARMACOKINETICS | SCHWARZ PHARMA AG (DE) | 2004-03-30 | — | — | US | disclosed |
| EP-1254890-A1 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2002-11-06 | — | — | EP | disclosed |
| EP-1077912-B1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2002-07-03 | — | — | EP | disclosed |
| EP-1077912-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058478-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042981-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | ADRB3, TNNI3, ADRB2 | LRRK2 2596/4885CCR5 3023/4885PTGER1 457/4885 |
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | ADRB3, ADRA1D, TNNC1 | LRRK2 3625/4885CCR5 2658/4885PTGER1 361/4885 |
| US-20060270738-A1 | Novel derivatives of 3,3-diphenylpropylamines | ADRB3, ADRA1D, TNNC1 | LRRK2 3625/4885CCR5 2658/4885PTGER1 361/4885 |
| US-20100256231-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | ADRB3, TNNI3, ADRB2 | LRRK2 2596/4885CCR5 3023/4885PTGER1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.